<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02586246</url>
  </required_header>
  <id_info>
    <org_study_id>1226-CL-A003</org_study_id>
    <secondary_id>275-10-001</secondary_id>
    <nct_id>NCT02586246</nct_id>
  </id_info>
  <brief_title>Long-term Treatment Study of CDP870 Self-injection in Patients With Active Rheumatoid Arthritis Who Are Participating in the Long-term Treatment Studies (Study 275-08-002 or Study 275-08-004) of CDP870</brief_title>
  <official_title>Long-term Treatment Study of CDP870 Self-injection. A Multicenter, Open-label, Long-term Safety Study to Evaluate the Safety and Efficacy of CDP870 Self-injection Administered at a Dose of 200 mg Biweekly for 24 Weeks or Longer in Patients With Active Rheumatoid Arthritis Who Are Participating in the Long-term Treatment Studies (Study 275-08-002 or Study 275-08-004) of CDP870 Administered Concomitantly With or Without Methotrexate (MTX)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>UCB Japan Co. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the safety and efficacy of CDP870 self-injection
      administered for 24 weeks or longer in subjects who are participating in the long-term
      treatment study (Study 275-08-002 or Study 275-08-004) of CDP870 administered concomitantly
      with or without Methotrexate.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of subjects experiencing at least one adverse event or at least one serious adverse event during the study</measure>
    <time_frame>The dosing was allowed until launch of certolizumab pegol for RA in Japan. The maximum duration on study drug was 116 weeks.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of subjects who meet the American College of Rheumatology 20% (ACR20) criteria at Week 12</measure>
    <time_frame>at Week 12</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of subjects who meet ACR20 criteria at Week 24</measure>
    <time_frame>at Week 24</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of subjects who meet the American College of Rheumatology 50% (ACR50) criteria at Week 12</measure>
    <time_frame>at Week 12</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of subjects who meet the American College of Rheumatology 50% (ACR50) criteria at Week 24</measure>
    <time_frame>at Week 24</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of subjects who meet the American College of Rheumatology 70% (ACR70) criteria at Week 12</measure>
    <time_frame>at Week 12</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of subjects who meet the American College of Rheumatology 70% (ACR70) criteria at Week 24</measure>
    <time_frame>at Week 24</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">86</enrollment>
  <condition>Active Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>CDP870 group from Study 275-08-002</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with active rheumatoid arthritis who are participating in Study 275-08-002 of CDP870</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CDP870 group from Study 275-08-004</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with active rheumatoid arthritis who are participating in Study275-08-004 of CDP870</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CDP870</intervention_name>
    <description>Self-injection</description>
    <arm_group_label>CDP870 group from Study 275-08-002</arm_group_label>
    <arm_group_label>CDP870 group from Study 275-08-004</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects who have completed the treatment in the parent clinical studies (NCT00851318
             and NCT00850343) up to 52 weeks

          -  Subjects who are willing to undertake self-injection and provide a written consent

        Exclusion Criteria:

          -  Patients with serious adverse events

          -  Patients who are judged by the investigator/subinvestigator to be ineligible to
             participation in the study for reasons such as uncooperative attitude or nonadherence
             to study procedures.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Astellas Pharma Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Aichi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gunma</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hiroshima</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hokkaido</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hyogo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kagawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kagoshima</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kanagawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kumamoto</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nagasaki</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oita</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saitama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tokushima</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>https://www.astellasclinicalstudyresults.com/hcp/study.aspx?ID=1226-CL-A003</url>
    <description>Link to results on Astellas Clinical Study Results Web site</description>
  </link>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 23, 2015</study_first_submitted>
  <study_first_submitted_qc>October 23, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 26, 2015</study_first_posted>
  <last_update_submitted>November 13, 2015</last_update_submitted>
  <last_update_submitted_qc>November 13, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 16, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CDP870</keyword>
  <keyword>Rheumatoid arthritis</keyword>
  <keyword>Long-term</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Certolizumab Pegol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

